This site is intended for healthcare professionals
Clinical trials
  • Home
  • /
  • Clinical trials
  • /
  • Thyroid Cancer
  • /
  • Donafenib in 131I-Refractory Differentiated Thyroi...
Clinical trial

Donafenib in 131I-Refractory Differentiated Thyroid Cancer

Read time: 1 mins
Last updated:22nd Oct 2020
Status: Recruiting
Identifier: NCT03602495
Donafenib in 131I-Refractory Differentiated Thyroid Cancer

Brief Summary:
Donafenib for advanced 131I-refractory/resistant differentiated thyroid cancer(DTC).

Detailed Description:
This phase 3 study of donafenib, an oral multikinase inhibitor that targets Raf kinase and receptor tyrosine kinases, is to assess efficacy and safety in patients with 131I-refractory/resistant differentiated thyroid cancer.The study is a randomised,multicentre,double-blind,placebo-controlled,study.

Study Type: Interventional (Clinical Trial)
Estimated Enrollment: 204 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A Multicenter, Randomized, Double-Blind,Placebo-controlled,Phase 3 Trial of Donafenib in 131IRefractory Differentiated Thyroid Cancer
Actual Study Start Date: August 29, 2018
Estimated Primary Completion Date: December 2021
Estimated Study Completion Date: December 2021

- Experimental: Donafenib
- Placebo Comparator: Placebo

Category Value
Study type(s) Interventional
Estimated enrolment 204
Actual Study start date 29 August 2018
Estimated Study Completion Date 01 December 2021

View full details